BioNTech (BNTX) to Release Quarterly Earnings on Wednesday

BioNTech (NASDAQ:BNTX) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of $0.38 per share for the quarter. BioNTech has set its FY 2025 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 EPS. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Stock Up 2.1 %

NASDAQ:BNTX opened at $99.47 on Monday. The company has a market cap of $23.85 billion, a PE ratio of -47.37 and a beta of 0.30. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $115.49 and its two-hundred day moving average is $113.37.

Analyst Ratings Changes

Several brokerages have commented on BNTX. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Wells Fargo & Company began coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective for the company. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. Finally, BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.